Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03848845 · OUTCOME

Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2024-04-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline (Day 1) and up to approximately 178 weeks

What was measured

Participants with worst-case shift from baseline in corneal examination which included: clear, pseudophakia, nuclear sclerosis, cortical cataract and posterior subcapsular cataract by right eye, left eye and worse eye are presented as yes (Y), no (N) and missing. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Analysis population: All Treated Population

Groups in this outcome

Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion

Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion28

Reported measurements

Clear Indicator, Left eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion12Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported
Clear Indicator, Right eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion12Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported
Clear Indicator, worse eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion12Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported
Cortical Cataract Indicator, Left eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion7Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Cortical Cataract Indicator, Right eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion7Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Cortical Cataract Indicator, Worse eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion7Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Nuclear Sclerosis, Left eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion8Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Nuclear Sclerosis, Right eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion8Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Nuclear Sclerosis, Worse eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion8Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Posterior Subcapsular Cataract, Left eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion7Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Posterior Subcapsular Cataract, Right eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion7Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion4Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Posterior Subcapsular Cataract, Worse eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion6Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion4Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported
Pseudophakia, Left eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion11Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported
Pseudophakia, Right eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion12Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion2Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion1Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported
Pseudophakia, Worse eye

Baseline N, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion11Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion4Not reportedNot reportedNot reportedNot reported

Baseline N, Post-Baseline N=Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion3Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion10Not reportedNot reportedNot reportedNot reported

Baseline Y, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline N

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Y

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported

Baseline Missing, Post-Baseline Missing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Missing
    title
    Clear Indicator, Left eye
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Missing
    title
    Clear Indicator, Right eye
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Missing
    title
    Clear Indicator, worse eye
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Cortical Cataract Indicator, Left eye
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Cortical Cataract Indicator, Right eye
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Cortical Cataract Indicator, Worse eye
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        8
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Nuclear Sclerosis, Left eye
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        8
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Nuclear Sclerosis, Right eye
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        8
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Nuclear Sclerosis, Worse eye
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Posterior Subcapsular Cataract, Left eye
  11. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        4
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        2
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Posterior Subcapsular Cataract, Right eye
  12. categories
    1. measurements
      1. group Id
        OG000
        value
        6
      title
      Baseline N, Post-Baseline N
    2. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline N, Post-Baseline Y
    3. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline N, Post-Baseline N=Missing
    4. measurements
      1. group Id
        OG000
        value
        0
      title
      Baseline Y, Post-Baseline N
    5. measurements
      1. group Id
        OG000
        value
        4
      title
      Baseline Y, Post-Baseline Y
    6. measurements
      1. group Id
        OG000
        value
        3
      title
      Baseline Y, Post-Baseline Missing
    7. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline N
    8. measurements
      1. group Id
        OG000
        value
        1
      title
      Baseline Missing, Post-Baseline Y
    9. measurements
      1. group Id
        OG000
        value
        10
      title
      Baseline Missing, Post-Baseline Missing
    title
    Posterior Subcapsular Cataract, Worse eye
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    units
    Participants
description
Participants with worst-case shift from baseline in corneal examination which included: clear, pseudophakia, nuclear sclerosis, cortical cataract and posterior subcapsular cataract by right eye, left eye and worse eye are presented as yes (Y), no (N) and missing. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
groups
  1. description
    Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.
    id
    OG000
    title
    Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion
param Type
COUNT_OF_PARTICIPANTS
population Description
All Treated Population
reporting Status
POSTED
time Frame
Baseline (Day 1) and up to approximately 178 weeks
title
Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice